T_H1 cytokines induce senescence in AML

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Cancer testis antigen PRAME is overexpressed in malignancies but not normal cells.
• PRAME-specific T cells are investigated for acute myeloid leukemia (AML) therapy.
• The senescence-inducing activity of these T cells on AML cells is unstudied.

Purpose of the Study:

• To investigate the senescence-inducing activity of PRAME-specific T_H1 cells on AML cells.
• To elucidate the mechanisms by which T cells induce senescence in AML.
• To explore potential therapeutic strategies for AML leveraging T cell-mediated senescence.

Main Methods:

• Analysis of cell cycle and marker expression in AML cell lines (Kasumi, Nomo-1).
• Treatment with supernatants from antigen-stimulated PRAME-specific T_H1 cells.
• Assessment of cytokine effects (IFN-γ, TNF-α) and T cell subsets (Vδ2⁺, CMV-specific, PBMCs).

Main Results:

• Supernatants from PRAME-specific T_H1 cells induced senescence in AML cell lines via combined IFN-γ and TNF-α.
• IFN-γ and TNF-α from TCR-activated Vδ2⁺ or CMV-specific T cells also caused terminal growth arrest in AML cells.
• Patient-derived AML samples showed G1/0 arrest upon stimulation with T_H1 cytokines or PBMC supernatants.

Conclusions:

• Senescence is induced in AML cells by the combination of IFN-γ and TNF-α.
• These senescence-inducing cytokines can originate from engineered T cells or innate/virus-specific T cells.
• This finding highlights a novel mechanism for T cell-mediated AML therapy targeting non-expressed antigens.